Reuters

U.S. experts to review Biogen drug that could be first new Alzheimer's treatment in decades

Nov 3 (Reuters) - U.S. health experts this week will decide whether to recommend approval for Biogen Inc's (BIIB.O), opens new tab Alzheimer's drug, which could become the first new treatment for the ...
Medscape

Controversial Alzheimer's Drug Unlikely to Get the OK in Europe

At its November meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) voted against Biogen's controversial Alzheimer's drug aducanumab (Aduhelm), ...
The New York Times

What Are Clinical Trials, and How Do They Work?

A New York Times health reporter explains what clinical trials are, why they are important and how they can help inform us. Credit...Ricardo Tomás Supported by By Nina Agrawal Nina Agrawal is a health ...
Nature

Controversial New Alzheimer’s Drugs Offer Hope—But at a High Cost

One of neurologist Anelyssa D’Abreu’s least favorite tasks is giving her patients a dreaded diagnosis: early-stage Alzheimer’s disease. But it’s not quite as bad as it used to be. Today when they ask, ...